Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rectosigmoidoscopy vs. Colonoscopy for Assessing Ulcerative Colitis Activity

Reuters Health  |  October 30, 2015

NEW YORK (Reuters Health)—In most cases, rectosigmoidoscopy and colonoscopy assessments of disease activity in ulcerative colitis yield the same results, researchers report.

“In clinical practice, rectosigmoidoscopy is enough to assess endoscopic activity and endoscopic healing,” Dr. Jean-Frédéric Colombel from Icahn School of Medicine at Mount Sinai, N.Y., told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Colombel and colleagues in Spain, Belgium and California used data from the EUCALYPTUS trial of etrolizumab to evaluate whether endoscopic assessment limited to the rectosigmoid adequately represents endoscopic activity of the more proximal colon and how potential discrepancies might affect assessment of efficacy.

“To me the most surprising is that this was never studied,” Dr. Colombel said. “We relied so far on endoscopic exam of the rectum and sigmoid both in clinical practice and clinical trials without knowing if it reflects the ‘all picture.'”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The team analyzed 239 videos that included assessment of colonic segments proximal to the rectosigmoid region for disease activity and endoscopic healing. They graded endoscopic severity using the Mayo Clinic Score endoscopic subscore (MCSe) where active disease was defined as a score >1 and endoscopic healing was defined as MCSe<=1 or MCSe=0.

Rectosigmoidoscopy and colonoscopy analyses agreed in 230 of 239 videos, yielding a strong correlation between their scores (r=0.84), the researchers report in Gastroenterology, online Oct. 22.

In nine videos, rectosigmoidoscopy found evidence of healing, whereas colonoscopy of the more proximal colon found mucosal lesions.

When healing was defined as MCSe=0, there was near perfect correlation between the endoscopies (r=0.96), with only one video showing endoscopic healing in the rectosigmoid while significant mucosal lesions remained in the proximal colon.

According to the MCSe, disease was more severe in the rectum and sigmoid than in the proximal colon in all but 4.6% of individual reads, and this assessment was confirmed when MCSe was combined with the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).

“Because of its strong ability to detect active disease, rectosigmoidoscopy should be sufficient in clinical practice for evaluating previously diagnosed patients with new symptoms,” the researchers conclude. “However, in cases where rectosigmoidoscopy has detected endoscopic healing in response to induction therapy, but symptoms persist, performance of a more extensive examination with colonoscopy is justified.”

“In the clinical trial setting,” they add, “this study suggests that if endoscopic healing is defined as an MCSe=0, rectosigmoidoscopy is sufficient for efficacy analyses. However, if endoscopic healing is defined as an MCSe<=1, these preliminary data suggest that colonoscopy is better than rectosigmoidoscopy for assessing the full extent of endoscopic healing for efficacy analyses of experimental therapies.”

Dr. Marietta Iacucci, a gastroenterologist from the University of Calgary, Alberta, Canada, told Reuters Health by email, “Physicians should initially do a full colonoscopy to assess the extent and severity of ulcerative colitis. Once the extent is known, often flexible sigmoidoscopy may be enough to determine response to treatment.”

“In ulcerative colitis patients, a flexible sigmoidoscopy may be sufficient to assess inflammation and response to therapy,” she explained. “This is easier on the patient, as they do not require a full bowel cleansing, and can be done most often without requiring any sedation. It is also a much shorter procedure, perhaps seven minutes at most compared with 30 minutes for a full colonoscopy.”

Dr. Iacucci, who was not involved in the new research, added, “In patients who use topical rectal treatment, the rectum may heal but inflammation may remain further upstream in the colon. In these patients a full colonoscopy may be required to assess inflammation. In patients with left sided ulcerative colitis, the disease may extend in patients further upstream associated with a relapse. These patients may also require a colonoscopy, especially if their symptoms change. In patients with ulcerative colitis and primary sclerosing cholangitis, an inflammation of the bile ducts, the inflammation may be limited to the right colon and these patients may need a full colonoscopy to assess their symptoms. And finally, when a gastroenterologist wants to exclude a colon cancer, a full colonoscopy needs to be done.”

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:etrolizumabrectosigmoidoscopyulcerative colitis

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

    May 3, 2016

    NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…

    Case Report: Possible Overlapping Vasculitis & Ulcerative Colitis

    January 17, 2020

    Figure 1. The patient had nodular pus-filled cystic lesions with violaceous borders on his left ear, right cheek, fingers and legs. A 42-year-old man with a history of ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and chronic sinusitis was referred to a rheumatologist to evaluate for a possible diagnosis of systemic vasculitis. This patient had…

    Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis

    October 15, 2015

    NEW YORK (Reuters Health)—The human IgG1 anti-TNF antibody adalimumab is safe and effective for short- and long-term treatment, and the calcineurin inhibitor tacrolimus given short-term brings remission, in patients with refractory ulcerative colitis, according to two new studies in the Journal of Crohn’s and Colitis. In the first study, online Sept. 21, Dr. Tamas Molnar…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences